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Objectives: Sarcopenia refers to the involuntary loss of skeletal muscle and is a predictor of physical disability/
mortality. Its pathogenesis is poorly understood, although roles for altered hypoxic signaling, oxidative stress,
adipokines and inflammatory mediators have been suggested. Sarcopenia also occurs upon exposure to the
hypoxia of high altitude. Using data from the Caudwell Xtreme Everest expedition we therefore sought to
analyze the extent of hypoxia-induced body composition changes and identify putative pathways associated with
fat-free mass (FFM) and fat mass (FM) loss.
Methods: After baseline testing in London (75 m), 24 investigators ascended from Kathmandu (1300 m) to
Everest base camp (EBC 5300 m) over 13 days. Fourteen investigators climbed above EBC, eight of whom
reached the summit (8848 m). Assessments were conducted at baseline, during ascent and after one, six and
eight week(s) of arrival at EBC. Changes in body composition (FM, FFM, total body water, intra- and extra-
cellular water) were measured by bioelectrical impedance. Biomarkers of nitric oxide and oxidative stress were
measured together with adipokines, inflammatory, metabolic and vascular markers.
Results: Participants lost a substantial, but variable, amount of body weight (7.3± 4.9 kg by expedition end;
p< 0.001). A progressive loss of both FM and FFM was observed, and after eight weeks, the proportion of FFM
loss was 48% greater than FM loss (p< 0.008). Changes in protein carbonyls (p< 0.001) were associated with a
decline in FM whereas 4-hydroxynonenal (p< 0.001) and IL-6 (p< 0.001) correlated with FFM loss. GLP-1
(r=−0.45, p<0.001) and nitrite (r=−0.29, p< 0.001) concentration changes were associated with FFM loss.
In a multivariate model, GLP-1, insulin and nitrite were significant predictors of FFM loss while protein car-
bonyls were predicted FM loss.
Conclusions: The putative role of GLP-1 and nitrite as mediators of the effects of hypoxia on FFM is an intriguing
finding. If confirmed, nutritional and pharmacological interventions targeting these pathways may offer new
avenues for prevention and treatment of sarcopenia.
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1. Introduction
Sarcopenia is defined as a significant loss of fat free mass (FFM).
This can affect physical function and lead to an increased risk of phy-
sical disability and mortality [1]. The pathogenesis of sarcopenia is
likely to be multifactorial, and skeletal muscle hypoxia has been pro-
posed as a causal factor for muscle wasting and reduced contractility
[2–4].
Weight loss has been widely reported in hypoxic chamber experi-
ments and after sojourns at high altitude, with associations between
magnitude of loss and both duration of exposure to hypoxia and level of
hypoxemia [5–7]. Current evidence seems to point to an alteration of
appetite control and consequent reduction of energy intake as a de-
terminant of the weight loss, whereas energy expenditure (resting and
dietary induced thermogenesis) seems to be less affected [8]. More than
60% of the weight lost is typically composed of FFM leading to a decline
of muscle contractility and physical performance and, consequently, an
individual's capacity to cope with extreme environmental conditions
[9].
Changes in appetite hormones [(leptin, ghrelin, glucagon like pep-
tide 1 (GLP-1) and cholecystokinin K (CCK))] have been reported after
exposure to hypoxia [10–12]. In particular, the role of leptin and
ghrelin as causal factors in the reduction of energy intake has attracted
controversy after studies reported opposing associations of these ap-
petite hormones with weight loss [13–17]. Recently, a decreased se-
cretion of post-prandial GLP-1 was observed in healthy men exposed to
normobaric hypoxia. [18] Conversely, an in vitro study showed en-
hanced GLP-1 secretion after hypoxia-inducible factor-1α (HIF-1α)
knockdown in human adipocytes [19]. To the best of our knowledge,
the role of GLP-1 has never been investigated in humans exposed to
prolonged hypobaric hypoxia.
A key role in the onset of these adaptive metabolic responses is
played by inflammation and oxidative stress, which are enhanced under
conditions of low oxygen availability [7,20–22]. The consecutive dis-
ruption of intracellular redox balance and inflammation both con-
tribute to skeletal muscle mobilization [23,24]. Hypoxia disrupts the
efficiency of the mitochondrial electron transport chain, inducing
leakage of electrons to molecular oxygen and thereby generating re-
active oxygen species (ROS) [25]. Interleukin 1 (IL-1), interleukin 6 (IL-
6) and C-reactive protein (CRP) are often upregulated during expedi-
tions at high altitude [26], and mechanisms linked to skeletal muscle
wasting include activation of HIF-1α and NF-κB catabolic pathways and
inhibition of the anabolic mammalian target of rapamycin (mTOR)
pathway [27–29]. Nitric oxide (NO) metabolism is also influenced by
oxygen availability as demonstrated by raised levels of nitrite and ni-
trate (markers of NO production) and cyclic guanosine monophosphate
(cGMP, a biomarker of NO activity) during acclimatization to high al-
titude [30].
Therefore, physiological data and plasma samples from the 2007
Caudwell Xtreme Everest (CXE) expedition [31] could provide valuable
mechanistic insights into the relationship between hypoxia and FFM
loss whereby the extended duration at high altitude serves as a pa-
thogenic model of sarcopenia. We first assess body composition changes
(FM and FFM) and fluid shifts [total body water (TBW), intracellular
(ICW) and extracellular water (ECW)] that occurred during the ex-
pedition. We then evaluate the association between changes in FM and
FFM with a comprehensive panel of biomarkers of oxidative stress,
inflammation, NO bioavailability, appetite control and intermediary
metabolism to identify significant predictors of changes in FM and FFM
during prolonged exposure to hypoxia. We hypothesized that changes
in FFM would be associated with indices of oxidative stress and in-
flammation in this group of healthy individuals exposed to hypobaric
hypoxia during the CXE study.
2. Methods
The study was approved by the University College of London (UCL)
Research Ethics Committee, in accordance with the Declaration of
Helsinki. Verbal and written informed consent was obtained from all
subjects. The study took place between January and June 2007.
2.1. Subjects
Twenty-four healthy participants (18 male; mean age 34.9 yr; range
19–59 yr) who were investigators on the CXE 2007 research expedition
to Mount Everest participated in this study [31]. All participants were
sea level natives free of cardiovascular or respiratory disease. Criteria
for participation have been described in detail elsewhere [31].
2.2. Study protocol
The design and conduct of this study is described elsewhere [31].
Briefly, participants underwent baseline testing in London (altitude
75 m) before travelling by plane to Kathmandu, Nepal (1300 m). From
there they flew to Lukla (2800 m) on expedition day 1 and then trekked
to Everest Base Camp (EBC; 5300 m), arriving on expedition day 13.
The ascent profile, along with blood hemoglobin levels and oxygen
saturations, is detailed in Table S1 of the Online Supplementary
Material. Testing was conducted during the ascent in field laboratories
at Kathmandu (1300 m; day −3 to 0), Namche (3500 m; day 4–6),
Pheriche (4250 m; day 9–10), and at EBC (5300 m; day 15–17, EBC
week 1). The participants were divided into two subgroups, Group 1
(base-camp team) who subsequently remained at EBC for the duration
of the expedition (n=10) and Group 2 (climbing team; n=14) who
subsequently ascended above 5300 m, to a maximum of 8848 m on
Mount Everest; measurements were repeated in both groups at week 6
and week 8. Ambient temperatures were well controlled during testing
[31].
2.3. Dietary intake
Three meals were provided per day along with ample provision of
calorific snacks (chocolate, nuts, crisps, malt loaf, cheese, cured meat)
ad libitum, guaranteeing access to plenty of carbohydrates and protein
to cope with the increased energy cost of the walk /climb; fresh fruit
and vegetable intake was low at altitudes above 3500 m. An ample
supply of meals and snacks were maintained up to camp 2, beyond this
hot food consisted of dehydrated meals whilst snacks remained avail-
able.
2.4. Peripheral oxygen saturation
SpO2 was measured by an independent investigator on the morning
of the same day that blood was analyzed, after 10 min of rest, using a
pulse oximeter (Onyx 9500, Nonin, USA).
2.5. Anthropometry
Body weight (kg) was measured using mechanical Seca 761 scales
(Seca, Birmingham, UK), which were hand-calibrated. An independent
investigator recorded body weight to the nearest 0.5 kg with the par-
ticipant wearing base layers only. Height was measured using a por-
table stadiometer and recorded to the nearest 0.1 cm.
2.6. Body composition
Bioelectrical impedance measurements were taken after a 10 min
period of supine rest as the participant lay on a non-conducting air
mattress with their arms away from their torso and their legs separated.
Measurements were obtained before meals and after voiding. The
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participants wore base layers but removed shoes and socks. Aluminium
electrodes were placed on the right side over the metacarpophalangeal
joints and between the ulna-radial styloid processes of the wrist and
over the metatarsal phalangeal joints and between the malleoli of the
ankle. A hand-held, battery operated tetrapolar bioimpedance analyzer
(Bodystat®1500) was used to apply currents at multiple frequencies of
5, 50, 100 and 200 kHz. Total body water and extracellular water were
calculated by integral algorithms of the bioanalyser. We assumed that
water contributed 73% to FFM at normal hydration status. Intracellular
water was calculated as the difference between TBW and ECW. FM was
calculated as the difference between body weight and FFM.
2.7. Blood sampling and sample analysis
All blood samples were taken prior to any exercise protocols
scheduled for the day [31] and drawn from the antecubital vein. Plasma
was separated from blood cells by centrifugation of whole blood at
800×g for 15 min and immediately frozen in 1 ml aliquots in liquid
nitrogen. Samples were stored for the duration of the expedition in-
cluding their transport back to Kathmandu in liquid nitrogen, trans-
ported back to the UK on dry ice and kept at −40 °C in a commercial
cryostorage facility until analysis. Sample analysis began approximately
one year after start of biobanking (July 2007) and was completed
within 22 months (Aug 2008-May 2010).
2.8. Oxidative stress markers
Isoprostanes (8-iso-prostaglandin F-2α) and 4-hydroxy-2-nonenal
(4-HNE) were quantified using direct competitive enzyme im-
munoassay (Assay Designs, Ann Arbor, MI) and ELISA (OxiSelect HNE-
His Adduct ELISA kit, Cell Biolabs, San Diego, CA), respectively. Protein
carbonyls (ProCO) were quantified following derivatization with dini-
trophenylhydrazine using a commercial ELISA kit (OxiSelect STA-310;
Cell Biolabs).
2.9. Nitric oxide biomarkers
NO metabolite concentrations were quantified immediately after
thawing of frozen plasma aliquots in the presence of an excess of N-
ethylmaleimide (NEM, in PBS; 10 mM final concentration). For nitrite/
nitrate analysis, NEM-treated samples were deproteinized with ice-cold
methanol (1:1 v/v), cleared by centrifugation and subjected to analysis
by high pressure liquid chromatography using a dedicated nitrite/ni-
trate analyzer (ENO20, Eicom). Cyclic GMP was determined by com-
mercial immunoassay kits (R & D Systems, Abingdon, UK; Biomedica,
Vienna, Austria).
2.10. Inflammatory markers
Interleukin-6, tumour necrosis factor (TNF-α) and macrophage mi-
gration inhibitory factor (MIF) were quantified using xMAP technology
(Human-Cytokines-12-plex-panel, BioRad) on a Luminex/Bio-Plex-200
System with high-throughput fluidics (BioRad).
2.11. Glucose and insulin
Plasma glucose levels were measured with the glucose oxidase
method. Insulin levels were determined using the Bio-Plex-Pro-Human-
Diabetes 12-plex panel (BioRad).
2.12. Metabolic hormones and adipokines
Adiponectin, adipsin, ghrelin, glucose-dependent insulinotropic
polypeptide (GIP), GLP-1, glucagon, leptin, resistin, and visfatin were
measured with the Bio-Plex Pro-Human-Diabetes multiplex im-
munoassay panels (BioRad). Epinephrine and Norepinephrine were
quantified using a direct competitive enzyme immunoassay (Bi-CAT
ELISA, Alpco Diagnostics, Salem, NH). Lactate concentrations were
determined colorimetrically by coupled enzymatic reactions using
commercial assay kits (Sigma). Triiodothyronine (T3) was measured
using the rat thyroid hormone panel Milliplex MAP kit (Millipore; there
is no difference between rat and human T3).
2.13. Statistical analysis
Data were described as means±SD. Data were log-transformed if not
normally distributed (ΔSpO2, Δ4-HNE). T test for independent samples
were used to compare characteristics between groups 1 and 2 at baseline
and during the expedition. Linear mixed models for repeated measures
were used to analyze whether there were significant changes in body
composition during the expedition. Paired t-test was used to test within-
subject differences of FM and FFM and ECW and ICW at each phase.
Pearson's correlation was used to evaluate significant associations between
changes in body composition with metabolic, vascular and oxy-in-
flammatory biomarkers. For the correlation analysis, we applied the
Bonferroni correction to account for the multiple comparisons, and only
results with p<0.001 were considered as statistically significant.
Stepwise multiple linear regression was performed to identify significant
metabolic predictors explaining the loss of FFM during the CXE expedition.
Regression models include changes for significant biomarkers identified by
the correlation analyzes and measured during the different phases of the
expedition (n=138). Analyzes were conducted using SPSS-19 for
Windows and Sigmaplot-11 for Windows. P value was set at<0.05.
3. Results
3.1. Baseline characteristics
Twenty-four participants (14 climbing team and 10 base-camp
team) completed the eight-week expedition. Participants were pre-
dominantly male (18/5), with mean age and BMI of 34.9± 9.2 years
and 24.9± 2.8 kg/m2. Baseline body composition characteristics were
not significantly different between participants reaching the summit
and those residing at basecamp (Table 1).
3.2. Body composition
Participants lost a significant amount of weight, FM and FFM
throughout the expedition (Fig. 1A). Body weight change amounted to
−7.3± 4.9 kg (p<0.001) at the end of the expedition (Fig. 1B), which
was significantly higher in the climbing team compared to base-camp
team (−4.3± 9.1 kg, p=0.04, Fig. 2A). Body weight changes showed
remarkable inter-individual variability, with some participants
Table 1
Body composition characteristics of the CXE 2007 Expedition Team and comparison
between team members climbing above Everest Base Camp/reaching the summit (clim-
bers) and members residing at Everest Base Camp at the beginning of the expedition.
All Climbers Base Camp p
N 24 14 10 –
Gender (M/F) 18/6 12/2 6/4 –
Age, years 34.9± 9.2 35.7±6.8 33.8± 12.1 0.62
Weight, kg 77.6± 12.4 80.7±13.3 72.2± 9.5 0.08
Height, cm 176.2± 6.8 178.4± 5.9 172.7± 7.2 0.07
Body Mass Index, kg/m2 24.9± 2.8 25.2±3.2 24.1± 2.2 0.80
Fat mass, kg 14.1± 5.1 14.8±5.6 13.2± 4.5 0.45
Fat free mass, kg 63.4± 10.1 66.5±9.3 59.2± 10.1 0.08
Total body water, L 45.4± 7.1 47.4±6.4 42.6± 7.5 0.10
Extracellular water, L 19.1± 2.3 19.8±2.2 18.1± 2.3 0.08
Intracellular water, L 26.0± 4.6 27.2±1.1 24.2± 4.8 0.12
Data are presented as means± SD. N=number of subjects; M=Male; F=Female;
Independent t test was used to determine differences between the two groups.
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losing> 10 kg and others gaining a little in the climbers whereas
variability of weight change was lower for the base-camp team (see Fig.
S1 of the Online Supplementary Material for details). Overall, partici-
pants showed a progressive loss of both FM and FFM, but the proportion
of FFM loss was 48% greater than FM loss (p< 0.008) (Fig. 1B). After
eight weeks, the climbing team showed a greater loss of FFM (p=0.03,
Fig. 2B), whereas a significant difference in FM loss between the two
groups was found after one (p=0.02) and six (p=0.03) weeks of the
expedition (Fig. 2C).
Participants also experienced a significant decline in TBW, ECW and
ICW (Fig. 3A). Changes in TBW were −3.1±2.9 L, which accounted
for> 60% of FFM losses. The majority of TBW losses were accounted
for by changes in ICW (−2.2±1.7 L), which were significantly
(p=0.02) greater than ECW (−1.1±1.6 L) after eight weeks (Fig. 3B).
Fig. 1. Overall participant mean changes (± s.e) in body weight, fat mass (FM) and fat
free mass (FFM) during the expedition. Data are presented are absolute values (Fig. 1a)
and as changes (Δ) relative to baseline measured at sea level (London, Fig. 1b). Linear
mixed models for repeated measures were used to analyze whether there were significant
changes in body composition during the expedition for both sets of data. Paired t-test was
used to test for differences in losses of FM and FFM at each phase (Fig. 1b).
Fig. 2. Mean changes (± s.e) in body weight (A), fat free mass (FFM, B) and fat mass (FM, C) during the expedition in individuals attempting to/reaching the summit (climbers) or
residing at Everest Base Camp. Data were expressed relative to sea level (London). Linear mixed models for repeated measures were used to analyze whether there were significant
changes in body composition during the expedition. Independent t-test was used to test for differences in losses of weight, FM and FFM between the two groups at each phase.
Fig. 3. Mean changes (± s.e)in total body water (TBW), extracellular (ECW) and in-
tracellular (ICW) water during the expedition. Data are presented as absolute values
(Fig. 3a) and as changes in volume (Δ) relative to baseline measured at sea level (London,
Fig. 3b). Linear mixed models for repeated measures were used to analyze whether there
were significant changes in body composition during the expedition for both sets of data.
Paired t-test was used to test for differences in losses of ECW and ICW at each phase
(Fig. 3b).
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3.3. Metabolic, vascular and oxy-inflammatory biomarkers
With one exception, all plasma biomarkers showed significant
changes during the expedition (p< 0.001); only ghrelin concentrations
remained unchanged (p=0.54). Nitrite levels increased during the ex-
pedition, but a substantial drop was observed at eight weeks at high
altitude. Similarly, after an initial rapid increase during the ascent,
cGMP concentrations progressively declined during the remainder of
the expedition. Changes were more distinct for nitrate, which showed
levels below baseline in the last two weeks. ProCO (decline), 4-HNE
(increase), 8-isoPGF (increase), IL-6 (increase) showed significant
changes with prolonged exposure to hypoxia whereas minor changes
were seen for CRP and TNF-α. Increases in concentration during the last
two weeks of the expedition were seen with GLP-1, insulin, T3, adre-
nalin, glucagon, lactate, adiponectin, GIP, adipsin and visfatin.
Conversely, a decline was observed for noradrenalin, leptin and resistin
(see Fig. S2 of the Online Supplementary Material for details).
3.4. Correlation analyzes
We evaluated the association between changes in body composition
(weight, FFM and FM) with biomarkers of NO bioavailability, oxy-in-
flammatory stress, metabolic status and adipokines, and these results
are detailed in Table 2. Lower SpO2 was associated with a greater de-
crease in weight (r=0.49, p<0.001), FFM (r=0.38, p< 0.001) and
FM (r=0.32, p<0.001). Changes in nitrite concentrations were asso-
ciated with significant changes in FFM (r=−0.29, p<0.001) but not
with FM (r=−0.03, p=0.68). A decrease in ProCO was associated with
greater losses of body weight (r=0.55, p<0.001), FFM (r=0.42,
p<0.001) and FM (r=0.40, p<0.001). Conversely, weight
(r=−0.32, p<0.001) and FFM (r=−0.29, p< 0.001) losses were
associated with an increase in 4-HNE concentrations. The only in-
flammatory biomarker associated with body composition changes was
IL-6 (BW, r=−0.47; FM, r=−0.29; FFM, r=−0.38; p<0.001).
Changes in FM were associated with adrenalin (r=−0.32, p< 0.001)
and lactate (r=−0.29, p< 0.001) whereas changes in FFM were as-
sociated with GLP-1 (r=−0.47, p< 0.001), insulin (r=−0.36,
p<0.001), glucagon (r=−0.44, p< 0.001) and visfatin (r=−0.41,
p<0.001).
3.5. Stepwise multiple regression
FFM losses were predictive of changes in GLP-1 (B± SE,
−0.006± 0.001, p<0.001), insulin (B± SE, 0.002±0.001, p=0.01)
and nitrite (B± SE, −4.7± 2.2, p=0.03) in a fully adjusted multi-
variate model. Changes in ProCO (B± SE, 0.16±0.07, p=0.03) were
instead the only predictor of FM changes (Table 3).
Table 2
Correlation between changes (Δ) in body components with changes in biomarkers of oxygen exposure and biomarkers of nitric oxide (NO) activity, oxidative stress, inflammation and
metabolism (N=138).
Δ BW Δ FM Δ FFM
Hypoxia Δ SPO2 0.49 (p<0.001) 0.32 (p<0.001) 0.38 (p<0.001)
NO Pathway Δ NO2− −0.30 (p<0.001) −0.09 (p=0.27) −0.29 (p<0.001)
Δ NO3− −0.09 (p=0.26) 0.004 (p=0.96) 0.13 (p=0.11)
Δ cGMP −0.04 (p=0.58) −0.03 (p=0.68) −0.04 (p=0.61)
Oxidative Stress Δ ProCO 0.55 (p<0.001) 0.40 (p<0.001) 0.42 (p<0.001)
Δ 4-HNE −0.32 (p<0.001) −0.22 (p=0.009) −0.29 (p<0.001)
Δ isoPGF −0.12 (p=0.15) −0.10 (p=0.25) −0.10 (p=0.26)
Inflammation Δ IL-6 −0.47(p<0.001) −0.29 (p<0.001) −0.38 (p<0.001)
Δ CRP −0.03 (p=0.71) −0.06 (p=0.44) −0.03 (p=0.72)
Δ TNF-α −0.06 (p=0.49) 0.13 (p=0.13) −0.16 (p=0.07)
Metabolic Δ GIP −0.14 (p=0.08) 0.11 (p=0.17) −0.21 (p=0.01)
Δ Ghrelin −0.33 (p<0.001) −0.24 (p=0.004) −0.26 (p=0.002)
Δ GLP-1 −0.53 (p<0.001) −0.27 (p=0.003) −0.47 (p<0.001)
Δ Insulin −0.44 (p<0.001) −0.27 (p=0.003) −0.36 (p<0.001)
Δ T3 −0.10 (p=0.24) −0.18 (p=0.02) −0.005 (p=0.95)
Δ Adrenalin −0.29 (p<0.001) −0.32 (p<0.001) −0.17 (p=0.05)
Δ Nor-adrenalin 0.20 (p=0.02) 0.10 (0.26) 0.22 (p=0.01)
Δ Glucagon −0.48 (p<0.001) −0.21 (0.01) −0.44 (p<0.001)
Δ Lactate −0.22 (p=0.01) −0.29 (p<0.001) −0.10 (p=0.22)
Adipokines Δ Leptin 0.14 (p=0.09) 0.02 (p=0.74) 0.17 (p=0.04)
Δ Resistin −0.15 (p=0.07) −0.02 (p=0.80) −0.15 (p=0.07)
Δ Visfatin −0.45 (p<0.001) −0.23 (p=0.02) −0.41 (p<0.001)
Δ Adiponectin −0.04 (p=0.57) 0.06 (p=0.46) −0.09 (p=0.24)
Δ Adipsin −0.08 (p=0.31) −0.06 (p=0.44) −0.10 (p=0.23)
Coefficients of correlations r are shown (p value). We applied the Bonferroni correction to the correlation analysis to account for multiple comparisons, and only results with p< 0.001
were considered as statistically significant (highlighted in bold). BW: body weight; FM: fat mass; FFM: fat free mass; SPO2: oxygen saturation; NO2−: nitrite; NO3−: nitrate; cGMP: cyclic
guanylate monophosphate; ProCO: protein carbonyls; 4-HNE: 4-hydroxynonenal; isoPGF: 8-iso-15(S)-Prostaglandin F2α; IL-6: interleukin 6; CRP: C-reactive protein; TNF-α: tumour
necrosis factor α; GIP: gastric inhibitory polypeptide; GLP-1: glucagon-like peptide 1; T3: triiodothyronine.
Table 3
Stepwise multiple linear regression to identify significant metabolic predictors explaining
the loss of FFM and FM during the Caudwell Xtreme Everest Expedition.
B SE P
Dependent Variable: ΔFFM (R2=0.34)
Constant −1.47 0.31 < 0.001
ΔGLP−1 −0.006 0.001 < 0.001
ΔInsulin 0.002 0.001 0.01
ΔNO2− −4.7 2.2 0.03
Dependent Variable: ΔFM (R2=0.23)
ΔProCO 0.16 0.07 0.03
Regression models include changes for significant biomarkers identified by the correla-
tion analyzes and measured across the different study expedition phases (N=138).
Dependent variable is change in FFM. Independent variables in the FFM model were
changes in SPO2, nitrite (NO2−), cyclic guanosine mono phosphate (cGMP), protein
carbonyls (ProCO), interleukin 6 (IL-6), glucagon, visfatin, 4-hydroxynonenal (4-HNE)
and glucagon-like peptide 1 (GLP-1). Independent variables in the FM model were
changes in SPO2, protein carbonyl (ProCO), interleukin 6 (IL-6), adrenalin and lactate.
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4. Discussion
4.1. Summary of main findings
Our analyzes explored whether data from healthy humans exposed
to hypobaric hypoxia at high altitude could provide mechanistic clues
into the pathogenesis of sarcopenia and identify potential physiological
targets for intervention to preserve FFM in humans. First, we demon-
strated a significant direct association between lower oxygen satura-
tions and loss of FM and FFM. The correlation analyzes identified two
distinct groups of biomarkers: 1) compensatory – loss of FM and FFM
was associated with increased biomarker concentrations; and 2) sy-
nergistic – loss of FM and FFM was associated with decreased biomarker
concentrations. The former includes nitrite, 4-HNE, IL-6, GLP-1, insulin,
adrenalin, glucagon and visfatin, whereas the only biomarker to show
synergistic changes with FM and FFM was ProCO. The multivariate
analyzes provide further support for the role of GLP-1, nitrite and in-
sulin as mediators of FFM loss, whereas the only predictor of FM loss
were changes in ProCO concentrations.
4.2. Body composition
Data from previous studies have shown that the extent and rate of
weight loss is correlated with the rate, extent and duration of the ex-
posure to hypoxia [5,6,32–34], but the factors involved in the onset and
maintenance of this remain undetermined. Variability in the magnitude
of weight loss in the face of a consistent exposure (rate, extent and
duration) to hypobaric hypoxia in our participants is striking and
consistent with previous reports [5–7,34]. This variability in response
to a consistent stimulus provided the signal on which our analysis is
based. Since rate, extent and duration of the hypoxic stress experienced
during this expedition were virtually identical for all members of the
climbing and laboratory team the variability in response between the
two groups must therefore be due to either genetic or epigenetic dif-
ferences in metabolic phenotype. Differences in FM loss were particu-
larly striking (Fig. 2C) inviting speculation about differential fatty acid
handling, regulation of fat synthesis and lipolysis or a combination of
these factors between individuals with different levels of prior high
altitude experience (criteria for inclusion in the climbing team included
previous event-free ascents above 6500 m and over 8000 m for summit
climbers, whereas members of the laboratory staffmust have had event-
free exposure to altitudes> 4000 m [31]). Since those differences ap-
pear to resurface upon a subsequent hypoxic challenge already at
moderate altitudes (i.e. during the early phase of this study before se-
paration of the Core Team into EBC laboratory staff and climbers) and
are therefore related to the process of acclimatization to hypoxia this
aspect of metabolic regulation would seem to merit further study.
Processes regulating appetite and energy intake along with hypoxia-
induced suppression of skeletal muscle protein synthesis seem to have a
more prominent role than energy expenditure per se in driving weight
loss [8]. We could not directly test the specific contribution of these two
components to the individual changes in energy balance during the
expedition, but the significant association of satiety hormones (insulin,
GLP-1) with FFM loss and the greater body composition changes in
climbers may indicate that both sides of the energy balance equation
(lower energy intake and increased physical activity/energy ex-
penditure, in particular in the climbing group) could be involved. Al-
ternatively, hypoxia may directly suppress protein synthesis via the
mTOR/Akt pathways. However, none of these factors on their own can
possibly account for the observed differences in weight loss between
laboratory and climbing team (Fig. 2) as both groups adhered to the
exact same ascent profile until reaching EBC.
Weight losses of 2.4–5.0 kg have been reported during expeditions
to altitudes above 5000 m (duration: 14–47 days) [5,7,33,35]. The use
of hypoxic chambers, where food intake, temperature and exercise were
controlled in two independent studies, resulted in average weight loss
ranging from 5.0 to 7.4 kg in subjects exposed to hypobaric hypoxia
(simulated altitude of 8848 m) over 38 days [32,36], which are com-
parable to the mean weight loss observed in our cohort.
Our study showed that the FFM loss contributed to more than 50%
of total weight lost, which clearly deviates from the Forbes's theory
which states that approximately one-fourth of weight loss will be FFM
(i.e., ΔFFM/ΔWeight=~0.25) with the remaining three-fourths fat
mass [37,38]. The average water content of FFM is about 73% and
therefore it is not surprising that TBW accounted for the majority of
FFM losses [39]; however, the higher loss of ICW compared to ECW
indicates a highly catabolic state and mobilization of metabolically
active body cell mass [40]. These changes in body composition have
been a common observation in studies conducted at high altitude and it
could represent an adaptive protective mechanism under conditions of
reduced oxygen availability [9]. Murray &Montgomery have advanced
the hypothesis that free amino acids and ketone bodies may act as both
substrates and metabolic modulators to protect cells from the hypoxic
challenge by improving mitochondrial efficiency, activating ATP-sen-
sitive potassium channel and reducing the production of reactive
oxygen species [41]. The Operation Everest II chamber study reported a
2.5 kg loss of FM and a 4.9 kg loss of FFM [32] which are similar to the
changes reported in our study. Despite the significant difference in
physical exertion, this similarity in body composition changes would
seem to provide further support for the role of hypoxia as a key factor in
the pathogenesis of sarcopenia.
4.3. Oxidative stress and inflammation
Oxidative stress, chronic inflammation, and mitochondrial dys-
function all play important roles in muscle atrophy [42]. The interac-
tion of these factors may converge on several intracellular signaling
pathways, which affect the balance between protein synthesis and
breakdown, and induce apoptosis, underpinning the primary pathology
of significant muscle mass loss [43]. This model implies a predominant,
damaging role of ROS on skeletal muscle, but the physiological sig-
naling roles of ROS and NO generated during muscle contractile activity
cannot be dismissed [44]. In skeletal muscle, NAD(P)H oxidases and
nitric oxide synthases are the main producers of superoxide (O2−) and
NO, respectively, which may interact with each other to form the potent
oxidant, peroxynitrite (ONOO−) [45]. However, the ROS that seems to
play a major signaling role in the muscle is hydrogen peroxide (H2O2)
[44,46]. These reactive species are characterised by different chemical
properties which may activate a number of transcription factors (NF-kB,
AP-1, HSF-1 and Nrf2), modify protein activities and potentially induce
downstream redox effects such as stimulation of cytoprotective and
metabolic mechanisms such as autophagy, muscle repair and mi-
tochondrial biogenesis [44–46].
The univariate correlations show a significant association between
loss of FFM and plasma 4-HNE concentrations, suggesting the in-
volvement of oxidative stress (contributing to lipid oxidation) in muscle
mobilization. ProCO was the only significant predictor of FM loss in the
multivariate model. Plasma levels of ProCO are a measure of protein
oxidation promoted by ROS but, counter intuitively, the concentrations
of ProCO progressively decreased with FM mobilization. This might be
explained by a predominant utilisation under these conditions of pro-
teins as a metabolic fuel; alternatively, skeletal muscle turnover may be
enhanced to supply specific amino acids for which there is a higher
demand in hypoxia [41]. Another reason for the relatively greater
muscle loss in the context of the elevated inflammatory response may
be that the amino acid content of acute phase proteins is very different
to that of normally produced transport and structural proteins (and
indeed to that provided in most diets) [47]. Acute phase proteins have a
particularly high phenylalanine, tyrosine and tryptophan content; for
example, the phenylalanine content of acute-phase proteins is 105 g/kg
versus 40 g/kg in muscle, meaning that to build 100 g of acute-phase
protein one would need about 100×105/40 g of protein substrate from
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food or catabolism.
IL-6 concentrations were significantly elevated, and this was the
only pro-inflammatory marker associated with changes in FFM and FM.
The physiological role of IL-6 as either a pro-inflammatory cytokine or
adaptive myokine is still controversial [48], and our study was not
suited to distinguish between these roles. However, we speculate that
these two physiological functions may not be mutually exclusive but
rather be part of the same adaptive process; the inflammatory response
could be part of an immune, protective change induced by the hypoxic
stress whereas the myokine metabolic action could be involved in the
enhancement of muscular efficiency as part of the response to increased
energetic demands of the remaining muscle fibres, aimed at compen-
sating FFM loss.
A short exposure to a 4200 m simulated altitude increased IL-6
concentrations with and without exercise [49]. In 48 trekkers studied
over a 6-week ascent up to 5129 m, IL-6 and IL-17a levels were found to
be significantly higher at high altitude than at sea level, and exercise
led to a further significant increase in IL-6 but not IL-17 levels [50].
While IL-6 seems to be critically involved in hypoxia-induced adaptive
changes in muscle metabolism [51] it remains to be established whe-
ther these responses have also a defined role in the pathogenesis of
sarcopenia.
4.4. Nitric oxide
Nitrite and cGMP concentrations progressively increased during the
ascent and showed a slight decline after eight weeks, but concentrations
did not drop below baseline. Changes in nitrate concentrations were
more defined and a substantial decrease compared to baseline was
observed after six weeks. Levett et al. [30] have previously explored
part of these responses and interpreted them as being indicative of an
enhanced conversion of nitrate into nitrite and NO as a consequence of
prolonged hypoxic exposure. The novel finding of the current analysis is
the significant association between FFM loss and circulating nitrite
concentrations. Again, this could be part of an orchestrated compen-
satory response to enhance muscular energy efficiency under conditions
of low oxygen availability and reduced muscle mass. This hypothesis is
supported by the role of NO in mitochondrial biogenesis and efficiency
[52] as demonstrated by the enhanced Phosphate/Oxygen Ratio in
skeletal muscle after supplementation with dietary nitrate [53]. In ad-
dition, inorganic nitrate supplementation in participants exposed to
normobaric hypoxia increases exercise performance and reduces
oxygen consumption, effects which were significantly correlated with
post-supplementation plasma nitrite concentrations [54]. Of note, ske-
letal muscle has recently been proposed to act as endogenous nitrate
reservoir; thus, the increase in circulating nitrite may be secondary to
the reduction of released nitrate [55].
4.5. Metabolic responses
GLP-1 is an incretin hormone secreted by L-cells in the small in-
testine in response to eating and is involved in the regulation of glucose
levels, gastric emptying and appetite [56]. GLP-1 also appears to cause
insulin-independent vasodilation and potently stimulates NO synthase
phosphorylation in endothelial cells [57]. Moreover, GLP-1 recruits
muscle microvasculature, which is associated with increased muscle
glucose utilisation, plasma NO metabolite concentrations, muscle in-
terstitial oxygenation as well as insulin clearance and uptake [58]. Our
results clearly highlight the pleiotropic effects of hypoxia on multiple
metabolic pathways. FM mobilization was associated with increased
concentrations of counter-regulatory hormones such as adrenalin and
lactate as they are linked to activation of β-oxidation and anaerobic
metabolism. In a previous analysis, we demonstrated a significant as-
sociation between adrenalin and insulin sensitivity [20], suggesting an
activation of lipolytic pathways to satisfy enhanced energy demands. By
contrast, FFM loss was associated with increases in GLP-1, insulin and
glucagon concentrations. GLP-1 was the strongest predictor of FFM loss
in the multivariate model. This finding could have significant treatment
potential for the reduction of FFM loss under hypoxic conditions, which
might be achieved with the help of dipeptidyl peptidase-IV (DPP-IV)
inhibitors or GLP-1 analogues such as exendin-4, a pharmacological
approach now commonly used for diabetes treatment. Increases in GLP-
1 may represent a compensatory response to FFM loss to enhance
vascular/metabolic coupling in the muscle via a synergistic effect on
NO and insulin signaling pathways. Consistent with this notion, ex-
endin-4 improved islet transplantation outcome by rescuing pancreatic
islets from hypoxia-induced oxidative stress [59]. Exendin-4 has also
been shown to activate Nrf2, a transcription factor that plays a central
role in orchestrating cellular anti-oxidative defence and redox home-
ostasis, providing a potential mechanistic explanation for the anti-in-
flammatory effects of GLP-1 and its agonists [60]. Curiously, GLP-1
concentrations did not change in healthy, young men exposed to nor-
mobaric hypoxia for ten days [61], potentially highlighting funda-
mental differences between the effects of normobaric and hypobaric
hypoxia on human physiology [62].
We have previously described the development of increased insulin
resistance with prolonged exposure to hypobaric hypoxia [20]. How-
ever, the multivariate model reported in the present study suggests a
concomitant decline of FFM and insulin concentrations during the ex-
pedition. This result is not surprising considering that, after accounting
for other regulatory factors, it would be favourable in hypoxic condi-
tions to reduce the anabolic drive and enhance tissue mobilization and
energy release. In general, insulin levels tend to be increased during
prolonged exposure to hypoxia [63,64] whereas low levels of insulin
have been reported in studies with short hypoxic exposure and modest
altitudes [65].
4.6. Adipokines
Visfatin concentrations were significantly associated with FFM loss
in the univariate correlation analyzes, but visfatin was not a significant
predictor in the multivariate model. This adipokine is produced by
adipocytes and macrophages infiltrating adipose tissue but also gener-
ated in the liver and skeletal muscle [66]. Secretion of visfatin is sti-
mulated by inflammation and has insulin-mimetic effects such as: in-
creased glucose uptake in adipocytes and myocytes, suppression of
hepatic glucose release, and lipogenesis [67]. Ours is the first study to
investigate the association between hypoxia and visfatin in humans;
previous in vitro studies have shown an upregulation of visfatin gene
expression in adipocytes through the activation of the HIF-1α pathway
secondary to hypoxia [68,69].
4.7. Strengths and limitations
The main strengths of our current study are represented by the
number of subjects that participated in the eight–week expedition, the
consistency of hypoxic exposure pattern and variability of response in
the face of this consistent stimulus; (thereby providing an important
physiological signal), the depth and richness of physiological pheno-
typing, and the comprehensive nature of our biomarker profiling.
Another strength lies in the use of multiple biomarkers of oxidative
stress to explore the relationship between hypoxia and FFM loss, which
is unprecedented and uncommon for field studies. More often than not,
oxidative stress markers are used interchangeably with little con-
sideration as to their specificity, biological half-life and the nature of
the oxidative insult they represent. However, our study is not without
limitations. The use of BIA for the assessment of body composition at
high altitude has been challenged as changes in hydration may influ-
ence the accuracy of measurements [70,71]. However, the study used
multi-frequency BIA which allows the measurement of intra- and extra-
cellular compartments. Secondly, plasma osmolality during the ex-
pedition did not change, which rules out the potential interference of
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changes in hydration status on BIA measurements (Table S2 of the
Online Supplementary Material). Skinfold thickness was also measured
during the expedition to assess body composition changes, but the re-
sults obtained using this method were unreliable and have therefore not
been included in this report. Finally, the generalizability of these results
to the general population is limited and therefore results should be
interpreted with caution. However, the primary aim of the study was to
provide clues as to the effects of prolonged hypoxia on loss of FFM and
identify potential mechanisms involved in the development of sarco-
penia.
4.8. Implications for future research
Changes in GLP-1 and nitrite concentrations are significantly cor-
related (Fig. S3 of the Online Supplementary Material), and both are
significant predictors of FFM loss. These changes are likely to represent
integrated compensatory responses to increase blood flow, delivery of
nutrients and overall tissue metabolic capacity. The effects of these
pathways on skeletal muscle structure and performance could be tested
in future animal and human studies with exposure to normoxia and
hypoxia and supplementation with, for example, incretins (or DPP-IV
inhibitors) and dietary nitrate. Specifically we offer candidate me-
chanisms that can be further evaluated in patient groups where sarco-
penia is common including older patients and critically ill patients, or in
those susceptible to hypoxia as a result of cardiovascular or pulmonary
disease.
5. Conclusions
Exposure to hypobaric hypoxia resulted in a significant FFM loss
that was associated with increased levels of biomarkers of the NO
pathway (nitrite), markers of oxidative stress (4-HNE), inflammation
(IL-6) and metabolic efficiency (GLP-1, insulin). The putative role of
GLP-1 and nitrite as mediators of the effects of hypoxia on FFM is an
important finding. If confirmed, nutritional and pharmacological in-
terventions targeting GLP-1 and the Nitrite-Nitric Oxide pathways
could represent promising strategies to prevent loss of skeletal muscle
at high altitude and in susceptible patient groups.
Author contributions
M.P.W.G. and M.F. are the guarantors of this work and, as such, had
full access to all the data in the study and take responsibility for the
integrity of the data and the accuracy of the data analysis. L.W., M.S.,
M.P.W.G., M.F. wrote the manuscript and researched data; H.L.R.,
C.A.L., K.M. researched data; H.E.M., M.G.M., M.A.S. contributed to
discussion and reviewed/edited manuscript; B.O.F., M.K., D.S.M.,
D.Z.H.L. researched data, contributed to discussion and reviewed/
edited manuscript.
Conflict of interest statement
The authors have no conflict of interest to declare.
Acknowledgements
HLR was supported by the BBSRC and EPSRC (Warwick Systems
Biology Doctoral Training Centre). Caudwell Xtreme Everest is a re-
search project coordinated by the Centre for Altitude, Space and
Extreme Environment Medicine, University College London, UK; it was
funded from a variety of sources, most of which were not public (see
http://archive.xtreme-everest.co.uk/ for details). Part of the biomarker
work was supported by the Medical Research Council (Strategic
Appointment Scheme (to MF), and funds from the Faculty of Medicine,
University of Southampton (to MF). MF acknowledges ongoing support
by the UK Medical Research Council (G1001536). Some of this work
was carried out at the University of Southampton NIHR Biomedical
Research Centre and the ULCH NIHR Biomedical Research Centre.
Appendix A. Supporting information
Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.redox.2017.05.004.
References
[1] S. Ali, J.M. Garcia, Sarcopenia, cachexia and aging: diagnosis, mechanisms and
therapeutic options - A mini-review, Gerontology 60 (2014) 294–305.
[2] T.W. Buford, et al., Models of accelerated sarcopenia: critical pieces for solving the
puzzle of age-related muscle atrophy, Ageing Res. Rev. 9 (2010) 369–383, http://
dx.doi.org/10.1016/j.arr.2010.04.004.
[3] C. Di Giulio, G. Petruccelli, G. Bianchi, M. Cacchio, V. Verratti, Does hypoxia cause
sarcopenia? Prevention of hypoxia could reduce sarcopenia, J. Biol. Regul.
Homeost. Agents 23 (2009) 55–58.
[4] M.J. Jackson, A. McArdle, Role of reactive oxygen species in age-related neuro-
muscular deficits, J. Physiol. 594 (2016) 1979–1988, http://dx.doi.org/10.1113/
jp270564.
[5] S.J. Boyer, F.D. Blume, Weight loss and changes in body composition at high alti-
tude, J. Appl. Physiol.: Respir. Environ. Exerc. Physiol. 57 (1984) 1580–1585.
[6] N. Hamad, S.P. Travis, Weight loss at high altitude: pathophysiology and practical
implications, Eur. J. Gastroenterol. Hepatol. 18 (2006) 5–10.
[7] J.H. Macdonald, et al., Body composition at high altitude: a randomized placebo-
controlled trial of dietary carbohydrate supplementation, Am. J. Clin. Nutr. 90
(2009) 1193–1202, http://dx.doi.org/10.3945/ajcn.2009.28075.
[8] B. Kayser, S. Verges, Hypoxia, energy balance and obesity: from pathophysiological
mechanisms to new treatment strategies, Obes. Rev. 14 (2013) 579–592, http://dx.
doi.org/10.1111/obr.12034.
[9] S.L. Wing-Gaia, Nutritional strategies for the preservation of fat free mass at high
altitude, Nutrients 6 (2014) 665–681, http://dx.doi.org/10.3390/nu6020665.
[10] M.S. Westerterp-Plantenga, et al., Appetite at "high altitude" [operation Everest III
(Comex-'97)]: a simulated ascent of mount Everest, J. Appl. Physiol. 87 (1999)
391–399.
[11] M. Tschop, C.J. Strasburger, G. Hartmann, J. Biollaz, P. Bartsch, Raised leptin
concentrations at high altitude associated with loss of appetite, Lancet 352 (1998)
1119–1120, http://dx.doi.org/10.1016/s0140-6736(05)79760-9.
[12] E.M. Snyder, R.D. Carr, C.F. Deacon, B.D. Johnson, Overnight hypoxic exposure and
glucagon-like peptide-1 and leptin levels in humans, Appl. Physiol. Nutr.
Metab.=Physiol. Appl. Nutr. Et. Metab. 33 (2008) 929–935, http://dx.doi.org/10.
1139/h08-079.
[13] T. Morishima, K. Goto, Ghrelin, GLP-1, and leptin responses during exposure to
moderate hypoxia, Appl. Physiol. Nutr. Metab.=Physiol. Appl. Nutr. Et. Metab. 41
(2016) 375–381, http://dx.doi.org/10.1139/apnm-2015-0311.
[14] J. Sierra-Johnson, A. Romero-Corral, V.K. Somers, B.D. Johnson, Last Word on
Viewpoint: effect of altitude on leptin levels, does it go up or down? J. Appl.
Physiol. 105 (2008) 1691, http://dx.doi.org/10.1152/japplphysiol.90679.2008.
[15] L.K. Wasse, C. Sunderland, J.A. King, R.L. Batterham, D.J. Stensel, Influence of rest
and exercise at a simulated altitude of 4000 m on appetite, energy intake, and
plasma concentrations of acylated ghrelin and peptide YY, J. Appl. Physiol. 112
(2012) 552–559, http://dx.doi.org/10.1152/japplphysiol.00090.2011.
[16] D.P. Bailey, et al., Appetite and gut hormone responses to moderate-intensity
continuous exercise versus high-intensity interval exercise, in normoxic and hy-
poxic conditions, Appetite 89 (2015) 237–245, http://dx.doi.org/10.1016/j.appet.
2015.02.019.
[17] B.F. Palmer, D.J. Clegg, Ascent to altitude as a weight loss method: the good and
bad of hypoxia inducible factor activation, Obesity 22 (2014) 311–317, http://dx.
doi.org/10.1002/oby.20499.
[18] T. Debevec, E.J. Simpson, I.B. Mekjavic, O. Eiken, I.A. Macdonald, Effects of pro-
longed hypoxia and bed rest on appetite and appetite-related hormones, Appetite
107 (2016) 28–37, http://dx.doi.org/10.1016/j.appet.2016.07.005.
[19] Y. Kihira, et al., Deletion of hypoxia-inducible factor-1alpha in adipocytes enhances
glucagon-like peptide-1 secretion and reduces adipose tissue inflammation, PLoS
One 9 (2014) e93856, http://dx.doi.org/10.1371/journal.pone.0093856.
[20] M. Siervo, et al., Effects of prolonged exposure to hypobaric hypoxia on oxidative
stress, inflammation and gluco-insular regulation: the not-so-sweet price for good
regulation, PLoS One 9 (2014) e94915, http://dx.doi.org/10.1371/journal.pone.
0094915.
[21] H.K. Eltzschig, P. Carmeliet, Hypoxia and inflammation, New Engl. J. Med. 364
(2011) 656–665, http://dx.doi.org/10.1056/NEJMra0910283.
[22] T. Miyata, S. Takizawa, C. van Ypersele de Strihou, Hypoxia. 1. Intracellular sensors
for oxygen and oxidative stress: novel therapeutic targets, Am. J. Physiol. - Cell
Physiol. 300 (2011) C226–C231, http://dx.doi.org/10.1152/ajpcell.00430.2010.
[23] H. Hoppeler, M. Vogt, Muscle tissue adaptations to hypoxia, J. Exp. Biol. 204 (2001)
3133–3139.
[24] G. van Hall, Cytokines: muscle protein and amino acid metabolism, Curr. Opin.
Clin. Nutr. Metab. Care 15 (2012) 85–91, http://dx.doi.org/10.1097/MCO.
0b013e32834e6ea2.
[25] A.J. Murray, Metabolic adaptation of skeletal muscle to high altitude hypoxia: how
new technologies could resolve the controversies, Genome Med. 1 (2009) 117,
http://dx.doi.org/10.1186/gm117.
L. Wandrag et al. Redox Biology 13 (2017) 60–68
67
[26] G. Hartmann, et al., High altitude increases circulating interleukin-6, interleukin-1
receptor antagonist and C-reactive protein, Cytokine 12 (2000) 246–252, http://dx.
doi.org/10.1006/cyto.1999.0533.
[27] C. de Theije, F. Costes, R.C. Langen, C. Pison, H.R. Gosker, Hypoxia and muscle
maintenance regulation: implications for chronic respiratory disease, Curr. Opin.
Clin. Nutr. Metab. Care 14 (2011) 548–553, http://dx.doi.org/10.1097/MCO.
0b013e32834b6e79.
[28] S.L. Dodd, B.J. Gagnon, S.M. Senf, B.A. Hain, A.R. Judge, Ros-mediated activation
of NF-kappaB and Foxo during muscle disuse, Muscle Nerve 41 (2010) 110–113,
http://dx.doi.org/10.1002/mus.21526.
[29] F.B. Favier, et al., Downregulation of Akt/mammalian target of rapamycin pathway
in skeletal muscle is associated with increased REDD1 expression in response to
chronic hypoxia, Am. J. Physiol. - Regul. Integr. Comp. Physiol. 298 (2010)
R1659–R1666, http://dx.doi.org/10.1152/ajpregu.00550.2009.
[30] D.Z. Levett, et al., The role of nitrogen oxides in human adaptation to hypoxia, Sci.
Rep. 1 (2011) 109, http://dx.doi.org/10.1038/srep00109.
[31] D.Z. Levett, et al., Design and conduct of Caudwell Xtreme Everest: an observational
cohort study of variation in human adaptation to progressive environmental hy-
poxia, BMC Med. Res. Methodol. 10 (2010) 98, http://dx.doi.org/10.1186/1471-
2288-10-98.
[32] M.S. Rose, et al., Operation Everest. II: Nutrition and body composition, J. Appl.
Physiol. 65 (1988) 2545–2551.
[33] M. Tschöp, K.M. Morrison, Robert C. Roach, Peter D. Wagner, Peter H. Hackett
(Eds.), Hypoxia: From Genes to the Bedside, Springer, US, 2001, pp. 237–247.
[34] F. Armellini, et al., The effects of high altitude trekking on body composition and
resting metabolic rate, Horm. Metab. Res.=Horm.- und Stoffwechs.=Horm. Et.
Metab. 29 (1997) 458–461, http://dx.doi.org/10.1055/s-2007-979077.
[35] A.J. Dinmore, J.S. Edwards, I.S. Menzies, S.P. Travis, Intestinal carbohydrate ab-
sorption and permeability at high altitude (5730 m), J. Appl. Physiol. 76 (1994)
1903–1907.
[36] P.D. Wagner, Operation Everest II, High. Alt. Med. Biol. 11 (2010) 111–119, http://
dx.doi.org/10.1089/ham.2009.1084.
[37] S.B. Heymsfield, M.C. Cristina Gonzalez, W. Shen, L. Redman, D. Thomas, Weight
loss composition is one-fourth fat-free mass: a critical review and critique of this
widely cited rule, Obes. Rev. 15 (2014) 310–321, http://dx.doi.org/10.1111/obr.
12143.
[38] G.B. Forbes, Lean body mass-body fat interrelationships in humans, Nutr. Rev. 45
(1987) 225–231.
[39] K.R. Westerterp, Energy and water balance at high altitude, News Physiol. Sci.: Int.
J. Physiol. Prod. Jt. Int. Union Physiol. Sci. Am. Physiol. Soc. 16 (2001) 134–137.
[40] Z. Wang, et al., Body cell mass: model development and validation at the cellular
level of body composition, Am. J. Physiol. Endocrinol. Metab. 286 (2004)
E123–E128, http://dx.doi.org/10.1152/ajpendo.00227.2003.
[41] A.J. Murray, H.E. Montgomery, How wasting is saving: weight loss at altitude might
result from an evolutionary adaptation, Bioessay.: News Rev. Mol. Cell. Dev. Biol.
36 (2014) 721–729, http://dx.doi.org/10.1002/bies.201400042.
[42] M.H. Choi, J.R. Ow, N.-D. Yang, R. Taneja, Oxidative stress-mediated skeletal
muscle degeneration: molecules, mechanisms, and therapies, Oxid. Med. Cell.
Longev. 2016 (2016) 13, http://dx.doi.org/10.1155/2016/6842568.
[43] S.-J. Meng, L.-J. Yu, Oxidative stress, molecular inflammation and sarcopenia, Int.
J. Mol. Sci. 11 (2010) 1509–1526, http://dx.doi.org/10.3390/ijms11041509.
[44] M.J. Jackson, Reactive oxygen species in sarcopenia: should we focus on excess
oxidative damage or defective redox signalling? Mol. Asp. Med. 50 (2016) 33–40,
http://dx.doi.org/10.1016/j.mam.2016.05.002.
[45] K. Goljanek-Whysall, L.A. Iwanejko, A. Vasilaki, V. Pekovic-Vaughan, B. McDonagh,
Ageing in relation to skeletal muscle dysfunction: redox homoeostasis to regulation
of gene expression, Mamm. Genome. 27 (2016) 341–357, http://dx.doi.org/10.
1007/s00335-016-9643-x.
[46] H.S. Marinho, C. Real, L. Cyrne, H. Soares, F. Antunes, Hydrogen peroxide sensing,
signaling and regulation of transcription factors, Redox Biol. 2 (2014) 535–562,
http://dx.doi.org/10.1016/j.redox.2014.02.006.
[47] P.J. Reeds, C.R. Fjeld, F. Jahoor, Do the differences between the amino acid com-
positions of acute-phase and muscle proteins have a bearing on nitrogen loss in
traumatic states? J. Nutr. 124 (1994) 906–910.
[48] P. Munoz-Canoves, C. Scheele, B.K. Pedersen, A.L. Serrano, Interleukin-6 myokine
signaling in skeletal muscle: a double-edged sword? FEBS J. 280 (2013) 4131–4148,
http://dx.doi.org/10.1111/febs.12338.
[49] A.V. Caris, et al., Carbohydrate supplementation influences serum cytokines after
exercise under hypoxic conditions, Nutrients 8 (2016) 706, http://dx.doi.org/10.
3390/nu8110706.
[50] C.J. Boos, et al., High altitude and acute mountain sickness and changes in circu-
lating Endothelin-1, Interleukin-6, and Interleukin-17a, High. Alt. Med. Biol. 17
(2016) 25–31, http://dx.doi.org/10.1089/ham.2015.0098.
[51] B.K. Pedersen, et al., The metabolic role of IL-6 produced during exercise: is IL-6 an
exercise factor? Proc. Nutr. Soc. 63 (2004) 263–267, http://dx.doi.org/10.1079/
pns2004338.
[52] C.H. Tengan, G.S. Rodrigues, R.O. Godinho, Nitric oxide in skeletal muscle: role on
mitochondrial biogenesis and function, Int. J. Mol. Sci. 13 (2012) 17160–17184,
http://dx.doi.org/10.3390/ijms131217160.
[53] F.J. Larsen, et al., Dietary inorganic nitrate improves mitochondrial efficiency in
humans, Cell Metab. 13 (2011) 149–159, http://dx.doi.org/10.1016/j.cmet.2011.
01.004.
[54] J. Kelly, et al., Dietary nitrate supplementation: effects on plasma nitrite and pul-
monary O2 uptake dynamics during exercise in hypoxia and normoxia, Am. J.
Physiol. Regul., Integr. Comp. Physiol. 307 (2014) R920–R930, http://dx.doi.org/
10.1152/ajpregu.00068.2014.
[55] B. Piknova, et al., Skeletal muscle as an endogenous nitrate reservoir, Nitric Oxide:
Biol. Chem. 47 (2015) 10–16, http://dx.doi.org/10.1016/j.niox.2015.02.145.
[56] L.L. Baggio, D.J. Drucker Biology of Incretins: GLP-1 and GIP. Gastroenterology,
132, 2131–2157, doi: http://dx.doi.org/10.1053/j.gastro.2007.03.054.
[57] L. Ding, J. Zhang, Glucagon-like peptide-1 activates endothelial nitric oxide syn-
thase in human umbilical vein endothelial cells, Acta Pharmacol. Sin. 33 (2012)
75–81, http://dx.doi.org/10.1038/aps.2011.149.
[58] W. Chai, et al., Glucagon-like peptide 1 recruits microvasculature and increases
glucose use in muscle via a nitric oxide-dependent mechanism, Diabetes 61 (2012)
888–896, http://dx.doi.org/10.2337/db11-1073.
[59] M. Padmasekar, et al., Exendin-4 protects hypoxic islets from oxidative stress and
improves islet transplantation outcome, Endocrinology 154 (2013) 1424–1433,
http://dx.doi.org/10.1210/en.2012-1983.
[60] T. Zhou, M. Zhang, L. Zhao, A. Li, X. Qin, Activation of Nrf2 contributes to the
protective effect of Exendin-4 against angiotensin II-induced vascular smooth
muscle cell senescence, Am. J. Physiol. Cell Physiol. 311 (2016) C572–c582, http://
dx.doi.org/10.1152/ajpcell.00093.2016.
[61] I.B. Mekjavic, et al., The effect of normobaric hypoxic confinement on metabolism,
gut hormones, and body composition, Front. Physiol. 7 (2016) 202, http://dx.doi.
org/10.3389/fphys.2016.00202.
[62] J. Coppel, P. Hennis, E. Gilbert-Kawai, M.P. Grocott, The physiological effects of
hypobaric hypoxia versus normobaric hypoxia: a systematic review of crossover
trials, Extrem. Physiol. Med. 4 (2015) 2, http://dx.doi.org/10.1186/s13728-014-
0021-6.
[63] P.M. Young, et al., Operation Everest II: metabolic and hormonal responses to in-
cremental exercise to exhaustion, J. Appl. Physiol. 73 (1992) 2574–2579.
[64] R.C. Sawhney, A.S. Malhotra, T. Singh, Glucoregulatory hormones in man at high
altitude, Eur. J. Appl. Physiol. Occup. Physiol. 62 (1991) 286–291.
[65] G. D'Hulst, et al., Effect of acute environmental hypoxia on protein metabolism in
human skeletal muscle, Acta Physiol. 208 (2013) 251–264, http://dx.doi.org/10.
1111/apha.12086.
[66] T.B. Dahl, S. Holm, P. Aukrust, B. Halvorsen, Visfatin/NAMPT: a multifaceted
molecule with diverse roles in physiology and pathophysiology, Annu. Rev. Nutr.
32 (2012) 229–243, http://dx.doi.org/10.1146/annurev-nutr-071811-150746.
[67] P. Saddi-Rosa, C.S. Oliveira, F.M. Giuffrida, A.F. Reis, Visfatin, glucose metabolism
and vascular disease: a review of evidence, Diabetol. Metab. Syndr. 2 (2010) 21,
http://dx.doi.org/10.1186/1758-5996-2-21.
[68] K. Segawa, et al., Visfatin in adipocytes is upregulated by hypoxia through
HIF1alpha-dependent mechanism, Biochem Biophys. Res. Commun. 349 (2006)
875–882, http://dx.doi.org/10.1016/j.bbrc.2006.07.083.
[69] S.K. Bae, et al., Hypoxic induction of human visfatin gene is directly mediated by
hypoxia-inducible factor-1, FEBS Lett. 580 (2006) 4105–4113, http://dx.doi.org/
10.1016/j.febslet.2006.06.052.
[70] C.J. Boos, et al., Comparison of two methods of assessing total body water at sea
level and increasing high altitude, Clin. Physiol. Funct. Imaging 34 (2014) 478–484,
http://dx.doi.org/10.1111/cpf.12121.
[71] C.S. Fulco, R.W. Hoyt, C.J. Baker-Fulco, J. Gonzalez, A. Cymerman, Use of bioe-
lectrical impedance to assess body composition changes at high altitude, J. Appl.
Physiol. 72 (1992) 2181–2187.
L. Wandrag et al. Redox Biology 13 (2017) 60–68
68
